Corvus Pharmaceuticals (FRA:C17) Total Long-Term Liabilities : €0.77 Mil (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Corvus Pharmaceuticals Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Corvus Pharmaceuticals's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €0.77 Mil.

Corvus Pharmaceuticals Total Long-Term Liabilities Historical Data

The historical data trend for Corvus Pharmaceuticals's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Total Long-Term Liabilities Chart

Corvus Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Long-Term Liabilities

Get a 7-Day Free Trial

1.01

2.30

1.30

0.90

Corvus Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Long-Term Liabilities	Get a 7-Day Free Trial															-	-	-	0.90	0.77

Corvus Pharmaceuticals Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Corvus Pharmaceuticals Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (FRA:C17) » Definitions » Total Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

CRVS:USA

Address

901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Corvus Pharmaceuticals Headlines

No Headlines